Review of the novelties presented at the 28th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II);Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)

Revista de Neurologia

Volumn 57, Issue 6, 2013, Pages 269-281

  Fernández, Óscar ^a   Arnal García, Carmen ^b   Arroyo González, Rafael ^c   Brieva, Lluís ^d   Calles Hernández, M Carmen ^e   Casanova Estruch, Bonaventura ^f   Comabella, Manuel ^g   de las Heras, Virginia ^h   García Merino, Juan A ⁱ   Hernández Pérez, Miguel A ^j   Izquierdo, Guillermo ^k   Matas, Elisabet ^l   Meca Lallana, José E ^m   Mendibe Bilbao, María del Mar ⁿ   Muñoz García, Delicias ^o   Olascoaga, Javier ^p   Oreja Guevara, Celia ^c   Prieto, José M ^q   Ramió Torrentà, Lluís ^r   Rodríguez Antigüedad, Alfredo ^s   Saiz, Albert ^t   Téllez, Nieves ^u   Villar, Luisa M ^v   Tintoré, Mar ^g   more..

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL ARNAU DE VILANOVA   (Spain)

^e HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^l HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o HOSPITAL XERAL CÍES   (Spain)

^p HOSPITAL DONOSTIA   (Spain)

^q HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^r HOSPITAL JOSEP TRUETA   (Spain)

^s HOSPITAL DE BASURTO   (Spain)

^t HOSPITAL CLÍNIC   (Spain)

^u HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^v HOSPITAL RAMÓN Y CAJAL   (Spain)

more..

Author keywords

Biomarkers; Cognitive impairment; Demyelination; Multiple sclerosis; Neuroimaging; Remyelination

Indexed keywords

AQUAPORIN 4 ANTIBODY; BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATALIZUMAB;

ARTICLE; BRAIN ATROPHY; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEMYELINATION; FUNCTIONAL NEUROIMAGING; GENETIC SUSCEPTIBILITY; HEALTH PROGRAM; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIAL PROGENITOR CELL; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; REMYELINIZATION; RISK ASSESSMENT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM AGENTS; COGNITION DISORDERS; DISEASE PROGRESSION; EUROPE; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; IMMUNIZATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURAL STEM CELLS; NEUROIMAGING; NEUROLOGY; OLIGODENDROGLIA; PROGNOSIS; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84884180640     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5706.2013276     Document Type: Article

References (79)

1. Strijbis E, Kooi E, Van der Valk P, Polman C, Geurts J. Heterogeneity of cortical remyelination in multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
2. Eleuteri C, Veroni C, Umeton R, Annibali V, Ristori G, Salvetti M, et al. New enhancers of endogenous remyelination: an extensive in vitro and ex vivo screening. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
3. Lubetzki C. Remielynation. 28th Congress of the EuropeanCommittee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
4. Piaton G, Aigrot MS, Williams A, Moyon S, Tepavcevic V, Moutkine I, et al. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 2011; 134: 1156-67.
5. Huang JK, Jarjour AA, Nait OB, Kerninon C, Williams A, Krezel W, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 2011; 14: 45-53.
6. Magalon K, Zimmer C, Cayre M, Khaldi J, Bourbon C, Robles I, et al. Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol 2012; 71: 213-26.
7. Asp L, Kramer E, Lee Y, Zhang J, Pedre X, Argaw A, et al. Krüppel-like factor-6 is required for oligodendrocyte maturation and CNS myelination. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
8. Kuipers H, Yoon J, Vister J, Palmer T, Steinman L. Differential roles for the small heat shock protein alpha B-crystallin in cuprizone-induced de- and remyelination. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France,2012.
9. Mackay-Sim A, Feron F, Cochrane J, Bassingthwaighte L, Bayliss C, Davies W, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 2008; 131: 2376-86.
10. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004; 127: 1463-78.
11. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914-22.
12. Petzold A. Biological markers. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
13. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865-70.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol 2005; 58: 840-6.
16. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
17. Srivastava R, Aslam M, Kalluri R, Schirmer L, Buck D, Tackenberg B, et al. The potassium channel KIR4.1 as an immune target in multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
18. Villar LM, Masjuán J, González-Porque P, Plaza J, Sadaba MC, Roldán E, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555-9.
19. Villar LM, Masjuán J, González-Porque P, Plaza J, Sadaba MC, Roldán E, et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53: 222-6.
20. Jongen PJ, Nijeholt G, Lamers KJ, Doesburg WH, Barkhof F, Lemmens WA, et al. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur Neurol 2007; 58: 90-5.
21. Yablonskiy DA, Luo J, Sukstanskii AL, Iyer A, Cross AH. Biophysical mechanisms of MRI signal frequency contrast in multiple sclerosis. Proc Natl Acad Sci U S A 2012; 109: 14212-7.
22. Brettschneider J, Petzold A, Sussmuth SD, Landwehrmeyer GB, Ludolph AC, Kassubek J, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006; 21: 2224-7.
23. Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Soderstrom M, et al. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004; 10: 261-5.
24. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005; 233: 183-98.
25. Salzer J, Svenningsson A, Sundstrom P. Neurofilament lightas a prognostic marker in multiple sclerosis. Mult Scler 2010; 16: 287-92.
26. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391-403.
27. Baranzini SE, Mousavi P, Río J, Caillier SJ, Stillman A, Villoslada P, et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005; 3: e2.
28. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, et al. Genome-wide scan of 500,000 singlenucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-8.
29. Axtell RC, De Jong BA, Boniface K, Van der Voort LF, Bhat R, De SP, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-12.
30. Rudick RA, Ransohoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998; 50: 1294-300.
31. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferonbeta treatment in multiple sclerosis. Lancet 2003; 361: 2036-43.
32. Rudick RA, Rani MR, Xu Y, Lee JC, Na J, Shrock J, et al. Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis. PLoS One 2011; 6: e19262.
33. Sellebjerg F. Future use of biomarkers in daily clinical practice. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
34. Sawcer J. From the genes to MS. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
35. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-9.
36. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in MS. Nature 2012; 488: 508-11.
37. Brassat D. Expectation from omics in MS. I28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
38. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, Chen R, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-307.
39. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
40. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
41. Comabella M, Fernández M, Martín R, Rivera-Vallve S, Borrás E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010; 133: 1082-93.
42. Baranzini SE, Mudge J, Van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA, et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464: 1351-6.
43. Harbo H. Genetic aspects and gender differences in disease onset and progression. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
44. De Jager P. ICAM3 expression level integrates the effects of six MS susceptibility alleles. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
45. Esposito F, Lim E, Romeo M, Rodegher M, Sorosina M, Brambilla P, et al. A pharmacogenetic study on Italian, US and French MS patients reveals an SLC9A9 variant as a novel marker of response to interferon-beta. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
46. Comabella M, Fissolo N, Malhotra S, Nurtdinov R, Río J, Tur C, et al. Gene expression profiling study in multiple sclerosis patients responders and non-responders to treatment with glatiramer acetate. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
47. Macciardi F, Cohen JA, Comabella M, Comi G, Cutter G, Eyal E, et al. A Genetic model to predict response to glatiramer acetate developed from a genome wide association study (GWAS) [abstract]. Neurology 2012; 78 (Suppl 1): IN3-2.003.
48. Barkhof F. Demyelination and remyelination. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
49. Abdel-Fahim R, Mistry N, Mougin O, Blazejewska A, Gowland P, Evangelou N. Improved detection of cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
50. Eshaghi A, Bodini B, Ridgway G, García-Lorenzo D, Tozer D, Sahraian M, et al. Dynamic changes in grey matter volume over 5 years in primary progressive multiple sclerosis: a tensor-based morphometry study. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
51. Stankoff B, Freeman L, Bodini B, Bottin L, Chardain A, Lubetzki C, et al. Positron emission tomography (PET) and molecular imaging for multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
52. Stankoff B, Wang Y, Bottlaender M, Aigrot MS, Dolle F, Wu C, et al. Imaging of CNS myelin by positron-emission tomography. Proc Natl Acad Sci U S A 2006; 103: 9304-9.
53. Stankoff B, Freeman L, Aigrot MS, Chardain A, Dolle F, Williams A, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-(1)(1)C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol 2011; 69: 673-80.
54. Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012; 79: 523-30.
55. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012; 32: 1-5.
56. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, Lanyon R, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131: 808-17.
57. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78: 1315-22.
58. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95.
59. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20.
60. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 2010; 74: 1033-40.
61. Chataway J. The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS)? -a phase II trial. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
62. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebocontrolled, parallel-group trial. Lancet Neurol 2010; 9: 681-8.
63. Miller D. MR and OCT markers. 28th Congress of theEuropean Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
64. Schneider T, Wheeler-Kingshott CA, Alexander DC. In-vivo estimates of axonal characteristics using optimized diffusion MRI protocols for single fibre orientation. Med Image Comput Comput Assist Interv 2010; 13: 623-30.
65. Oh J, Saidha S, Chen M, Smith S, Prince J, Jones C, et al. Probing the clinico-radiological paradox of the spinal cord in multiple sclerosis with quantitative MRI. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
66. Gabilondo I, Saiz A, Martínez E, Fraga E, Llufriu S, Ortiz S, et al. Retinal atrophy and brain damage in MS: a model for trans-synaptic neuronal degeneration? 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
67. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol 2012; 11: 963-72.
68. Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010; 133: 847-57.
69. Zaaraoui W, Konstandin S, Audoin B, Nagel AM, Rico A, Malikova I, et al. Distribution of brain sodium accumulation correlates with disability in multiple sclerosis: a cross-sectional 23Na MR imaging study. Radiology 2012; 264: 859-67.
70. Giorgio A, De SN. Cognition in multiple sclerosis: relevance of lesions, brain atrophy and proton MR spectroscopy. Neurol Sci 2010; 31 (Suppl 2): S245-8.
71. De Stefano N. Morphological imaging.28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
72. Enzinger C. Functional imaging.28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
73. Wegner C, Filippi M, Korteweg T, Beckmann C, Ciccarelli O, De SN, et al. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol 2008; 15: 113-22.
74. Loitfelder M, Fazekas F, Petrovic K, Fuchs S, Ropele S, Wallner-Blazek M, et al. Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. Neurology 2011; 76: 526-33.
75. Giorgio A, Palace J, Johansen-Berg H, Smith SM, Ropele S, Fuchs S, et al. Relationships of brain white matter microstructure with clinical and MR measures in relapsingremitting multiple sclerosis. J Magn Reson Imaging 2010; 31: 309-16.
76. Benedict R, Hulst H, Bergland N, Schoonheim M, Dwyer M, Weinstock-Guttman B, et al. Relative contribution of thalamus volume and diffusion tensor metrics to cognitive impairment in multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
77. Filippi M, Rocca M, Valsasina P, Amato M, Absinta M, Ghezzi A, et al. Resting state functional connectivity abnormalities are associated with cognitive impairment in patients with paediatric multiple sclerosis. 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Lyon, France, 2012.
78. Fernández O, Arnal-García C, Arroyo-González R, Brieva LL, Calles-Hernández MC, Casanova-Estruch B, et al. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I). Rev Neurol 2013; 57: 217-29.
79. Fernández O, Arnal-García C, Arroyo-González R, Brieva LL, Calles-Hernández MC, Casanova-Estruch B,etal. Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (III). Rev Neurol 2013 [in press].